Sanofi has entered into a partnership with Brigham and Women’s Hospital (BWH) to focus on immunology of type 1 diabetes. Researchers from both organziations, who share knowledge and expertise in this area, will conduct studies that will create an immunomodulatory approach to treat type 1 diabetes. Both organziations are excited with this partnership and believe that with the resources from Sanofi and BWH, a breakthrough on new treatment options will be afforded to those individuals living with type 1 diabetes.

Read more about Sanofi’s partnership with BWH to work on immunology for type 1 diabetes.

About Sanofi
[small_ad_left]Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms; diabetes solutions, human vaccine, innovation drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit or call 1-800-981-2491.

Tweet me: #Sanofi and Teaching Hospital sign agreement for research on Type 1 #Diabetes #BrighamWomensHospital

Contact Info:

+1 (800) 981-2491

KEYWORDS: Sanofi, diabetes, teaching hospital, brigham and womens hospital, type 1 collboration

Associated Media:

Comments are closed.